Emese Zsiros, MD, PhD, FACOG, discusses the FDA approval of pembrolizumab plus paclitaxel with or without pembrolizumab for PD-L1–positive ovarian cancer.
Emese Zsiros, MD, PhD
Advertisement
Emese Zsiros, MD, PhD, is a professor of oncology, chair of the Department of Gynecologic Oncology, co-leader of the Tumor Immunology and Immunotherapy CCSG Program, and the Shahi Lele, MD, Endowed Chair in Gynecologic Oncology at the Roswell Park Comprehensive Cancer Center; as well as a clinical associate professor at the Jacobs School of Medicine and Biomedical Sciences at the State University of New York at Buffalo
Articles by Emese Zsiros, MD, PhD
Emese Zsiros, MD, PhD, discusses the results of her recent phase II trial that set out to evaluate the use of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
TALAPRO-3 Shows Talazoparib Plus Enzalutamide Improves rPFS in HRR-Altered mCSPC
3
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
4
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
5